BARCELONA, Spain, Nov. 7, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative ...

GigaGen announced that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of the first ...

Grifols (GRFS) stock falls as Brookfield Asset Management (BAM) considers a $6.9B offer, which has met with opposition from ...

Nov 18 (Reuters) - Canadian fund Brookfield (BN.TO), opens new tab plans to offer about 7 billion euros ($7.4 billion) for ...

Brookfield Asset Management is considering a €6.45 billion ($6.9 billion) bid for Grifols SA, with the drug maker’s board set ...

Mason Capital opposes Grifols sale to Brookfield Asset Management, raising concerns about the potential acquisition in the ...

Banks are getting ready to submit final offers to Brookfield Asset Management for a debt package of about €11 billion ($11.6 ...

Meanwhile, Grifols is also expecting great things for its recently FDA-approved intravenous immunoglobulin product Yimmugo, which it expects to become a $1 billion product within the next seven ...

Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division. Shares traded 4.7% higher ...

Brookfield still hasn't managed to obtain the €9.5 billion of bank financing to repay Grifols’ debt, nor the €3.5 billion it ...